title: [Efficacy and safety of enoxaparin use during drug-eluting stents implantation].
abstract: We assessed possibility of the use of low molecular heparin enoxaparin during percutaneous coronary interventions (PCI) with implantation of drug eluting stents. Enoxaparin was administered to 225 (0.3 mg/kg intraarterially via catheter) and 215 (0.5 mg/kg intravenously) patients. In comparison group (n=207) we used unfractionated heparin (UFG) intravenously according to standard scheme under control of activated clotting time. Stents implanted (n=797) were Cypher, Taxus, and Endeavor. Immediate angiographic success was 100%. During 48 hours after PCI pronounced bleeding (4.3%) and blood transfusions predominated in UFG treated patients. Number of bleedings was minimal after the intra-arterial use of enoxaparin (0.3 mg/kg). However total rate of all adverse events after PCI turned out to be minimal (7.0%) in the group of patients receiving enoxaparin intravenously (0.5 mg/kg). Thus the use of low molecular heparin enoxaparin is justified during implantation of drug eluting stents. Its optimal dose according to data obtained is 0.5 mg/kg intravenously.
authors: F
authors: F
authors: Mustafaoglu
authors: L N
authors: LN
authors: Petrakova
authors: I V
authors: IV
authors: Pershukov
authors: T A
authors: TA
authors: Batyraliev
authors: Iu V
authors: IuV
authors: Pia
authors: I A
authors: IA
authors: Lazarev
authors: D M
authors: DM
authors: Ramazanov
authors: L V
authors: LV
authors: Shul'zhenko
authors: B K
authors: BK
authors: Kadyrov
authors: D V
authors: DV
authors: Sal'nikov
authors: N N
authors: NN
authors: Dolgikh
authors: B A
authors: BA
authors: Sidorenko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000379:methods*; D004562:Electrocardiography; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D012189:Retrospective Studies; D015607:Stents; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D017984:Enoxaparin; D005343:Fibrinolytic Agents